Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 295-302

  Zhang, Shengle ^a   Zhang, Helen S ^a   Reuter, Victor E ^a   Slovin, Susan F ^a   Scher, Howard I ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN BETA SUBUNIT; GANGLIOSIDE GM2; ONCOPROTEIN; TUMOR ANTIGEN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TISSUE DISTRIBUTION; TUMOR BIOPSY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CARBOHYDRATE SEQUENCE; EPITOPES; HUMANS; IMMUNOTHERAPY; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 0031912919     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Zhang, S., Cordon-Cardo, C., Zhang, H. S., Reuter, V. E., Adluri, S., Hamilton, W. B., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on gangliosides. Int. J. Cancer, 73: 42-49, 1997.
2. Zhang, S., Zhang, H. S., Cordon-Cardo, C., Reuter, V. E., Singhal, A. K., Lloyd, K. O., and Livingston, P. O. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int. J. Cancer, 73: 50-56, 1997.
3. Shitara, K., Fujiwara, K., Igarashi, S., Ohta, S., Furuya, A., Nakamura, K., Koike, M., and Hanai, N., Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG. J. Immunol. Methods, 169: 83-92, 1994.
4. Longenecker, B. M., Rahman, A. F. R., Leigh, J. B., Purser, R. A., Greenberg, A. H., Willans, D. J., Keller, O., Petrik, P. K., Thay, T. Y., Suresh, M. R., and Noujaim, A. A. Monoclonal antibody against a cryptic carbohydrate antigen of murine and human lymphocytes. I. Antigen expression in non-cryptic or unsubstituted form on certain murine lymphomas, on a spontaneous murine mammary carcinoma, and on several human adenocarcinomas. Int. J. Cancer, 33: 123-129, 1984.
5. Colcher, D., Horan Hand, P., Nuti, M., and Schlom, J., A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA. 78: 3199-3203, 1981.
6. Menard, S., Tagliabue, E., Canevari, S., Fossati, G., and Colnaghi, M. I., Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res., 43: 1295-1300, 1983.
7. y determinants. Proc. Natl. Acad. Sci. USA, 91: 12957-12965, 1994.
8. Taylor-Papadimitriou, J., Peterson, J. A., Arklie, J., Burchell, J., Ceriani, R. L., and Bodmer, W. F. Monoclonal antibodies to epithelium specific components of the milk fat globule membrane: production and reactions with cells in culture. Int. J. Cancer, 28: 17-21, 1981.
9. Gambus, G., Bolos, C. D., Andreu, D., Franci, C., Egea, G., and Real, F. X. Detection of the MUC2 apomucin tandem repeat with a mouse monoclonal antibody. Gastroenterology, 104: 93-102, 1993.
10. Apostolopoulos, V., Xing, P-X., and Mckenzie, I. F. C. Anti-peptide monoclonal antibodies to intestinal mucin 3. J. Gastroenterol. Hepatol., 10: 555-561, 1995.
11. Xing, P. X., Prenzoska, J., Apostolopoulos, V., Karkaloutsos, J., and McKenzie, I. F. C. Monoclonal antibodies to MUC4 peptide react with lung cancer. Int. J. Oncology, in press, 1998.
12. Reis, C., David, L., Nielsen, P. A., Clausen, H., Mirgorodskaya, K., Roepstorff, P., and Sobrinho-Simoes, M. Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody. Int. J. Cancer, 74: 112-121, 1997.
13. Nielsen, P. A., Bennett, E. P., Wandall, H. H., Therkildsen, M. H., Hannibal, J., and Clausen, H. Identification of a major human high molecular weight salivary mucin (MG1) as tracheobronchial mucin MUC5B. Glycobiology, 7: 413-419, 1997.
14. Nielsen, P. A., Mandel, U., Therkildsen, M. H., and Clausen, H., Differential expression of human high molecular weight salivary mucin (MG1) and low molecular weight salivary mucin (MG2). J. Dent. Res., 75: 1820-1826, 1996.
15. Horoszewicz, J. S., Kawinski, E., and Murphy, G. P. Monoclonal antibodies to new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res., 7: 927-936, 1987.
16. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W., and Cordon-Cardo, C. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res., 3: 81-85, 1997.
17. Heston, D. W. Biologic implications for prostatic function following identification of prostate-specific membrane antigen as a novel folate hydrolase/neurocarboxypeptidase. In: R. K. Naz, ed., Prostate: Basic and Clinical Aspects, pp. 267-294. New York: CRC Press, 1997.
18. Herlyn, D., Herlyn, M., Ross, A. H., Ernst, C., Atkinson, B., and Koprowski, H. Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J. Immunol. Methods, 73: 157-167, 1984.
19. Bellet, D. H., Ozturk, M., Bidart, J. M., Bouhuon, C. J., and Wands, J. R. Sensitive and specific assay for human chorionic gonadotropin (hCG) based on anti-peptide and anti-hCG monoclonal antibodies: construction and clinical implications. J. Clin. Endocrinol. Metab., 63: 1319-1326, 1986.
20. Coussens, L., Yang-Feng, T. L., Chen, Y. L. E., Gray, A., McGrath, J., Seeburg, P. H., Liberman, T. A., Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Washington DC), 230: 1132-1139, 1986.
21. Hsu, S. M., Rain, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immuoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
22. 131I-CC49: outcomes in patients with androgen independent prostate cancer. Clin. Cancer Res., in press, 1998.
23. Livingston, P. O., Ritter, G., Srivastava, P., Padavan, M., Calves, M. J., Oettgen, H. F., and Old, L. J. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res., 49: 7045-7050, 1989.
24. Livingston, P. O., Wong, G. Y., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., and Ritter, G. Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
25. Livingston, P. O. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev., 145: 147-166, 1995.
26. Morton, D. L., Foshag, L. J., Hoon, D. S., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Irie, R. F., Gupta, R. K., and Elashioff, R., Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann. NY Acad. Sci., 690: 120-134, 1993.
27. MacLean, G. D., Reddish, M. A., Koganty, R. R., and Longenecker, B. M. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic sTn vaccine. J. Immunol., 19: 59-68, 1996.
28. Adluri, S., Helling, F., Calves, M. J., Lloyd, K. O., and Livingston, P. O. Immunogenicity of synthetic TF- and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother., 41: 185-192, 1995.
29. Gilewski, T., Adluri, R., Houghton, A., Norton, L., and Livingston, P., Preliminary results: vaccination of breast cancer patients lacking identifiable disease with MUC1-keyhole limpet hemocyanin (KLH) conjugate and QS21. Proc. Am. Soc. Clin. Oncol., 15: 555, 1996.
30. Jones, W. R., Judd, S. J., Ing, R. M. Y., Powell, J., Bradley, J., Denholm, E. H., Mueller, U. W., Griffen, P. D., Stevens, V. C. Phase I clinical trial of a World Health Organisation birth control vaccine. Lancet, 1: 1295-1298, 1988.
31. Cheung, N-K. V., Lazarus, H., Miraldi, F. D., Abramowaky, C. R., Kallic, S., Saarinen, U. M., Spitzer, T., Strandjord, S. E., Coccia, P. F., and Berger, N. A. Ganglioside GD2 specific monoclonal antibody 3F8: a Phase-I study in patients with neuroblastoma and malignant melanoma. J. Clin. Oncol., 5: 1430-1440, 1987.
32. Houghton, A. N., Mintzer, D., Cordon-Cardo, C., Welt, S., Fliegel, B., Vadhan, S., Carswell, E., Melamed, M. R., Oettgen, H. F., and Old, L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a Phase-I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. USA, 82: 1242-1246, 1985.
33. Dippold, W. G., Bernhard, H., Dienes, H. P., and Meyer zum Buschenfelde, K. H. Treatment of patients with malignant melanoma by monoclonal ganglioside antibodies. Eur. J. Cancer Clin. Oncol., 24: S65-S67, 1988.
34. Riethmuller, G., Schneider-Gadicke, E., Schlimok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
35. Cascinelli, N., Doci, R., Nava, F. M., Belli, F., Marolda, R., Costa, A., Menard, S., and Terno, G. Evaluation of toxic effects following administration of monoclonal antibody MBr1 in patients with breast cancer. Tumori, 72: 267-271, 1986.
36. Saleh, M. N., Khazaeli, M. B., Wheeler, R. H., Dropcho, E., Liu, T., Urist, M., Miller, D. M., Lawson, S., Dixon, P., Russell, C. H., and LoBuglio, A. F. Phase I trial of the murine monoclonal anti-GD2 antibody 14G9a in metastatic melanoma. Cancer Res., 52: 4342-4347, 1992.
37. Mordoh, J., Silva, C., Albarellos, M., Bravo, A. I., and Kairiyama, C., Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells. J. Immunother., 17: 151-180, 1995.
38. Capurro, M., Bover, L., Portela, P., Livingston, P. O., and Mordoh, J. FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis X hapten. Cancer Immunol. Immunother., in press, 1998.